CD44 blockade may reshape pancreatic tumor support tissue and improve therapy
Scientists at the Karlsruhe Institute of Technology found that CD44 helps drive the activated state of connective-tissue cells that shield pancreatic tumors. When they removed CD44 activity in mouse and human cell experiments, those cells made less structural matrix and fewer signaling molecules and no longer dampened immune responses. The work points to reprogramming this protective tissue as a way to make pancreatic cancer more responsive to treatment.
Pancreatic tumors often contain a large protective microenvironment, with supporting tissue making up as much as nine-tenths of tumor mass. Within it, cancer-associated fibroblasts build scar-like material and release signals that restrain immune attack, helping the cancer grow and resist treatment.
In experiments using mouse models and human cells, KIT researchers found CD44 strengthens activation signals in these fibroblasts. Removing CD44 reduced matrix production and cytokine release, restored immune-cell activity, and shrank tumors in mice. Earlier KIT work targeted a CD44 variant with a peptide tested clinically; the new findings suggest targeting CD44 in this surrounding tissue may also be worth pursuing, though clinical use requires more study.
If confirmed, this approach could matter most for pancreatic cancer patients, whose treatment options are limited and whose tumors often resist immunotherapy. By aiming at the protective tissue rather than destroying it, a CD44-directed strategy may offer a less disruptive way to make existing therapies work better. Families and clinicians could benefit from improved response rates, but benefits remain speculative until human trials show safety and efficacy; patients should not expect immediate changes.